ConductScience.org, home

Paper18596265

Heparan sulfate in perlecan promotes mouse atherosclerosis: roles in lipid permeability, lipid retention, and smooth muscle cell proliferation.

Tran-Lundmark K and 9 others. Circ Res, 2008. Cited by 87 papers, by iCite.

Cite this record

ConductScience Library. Heparan sulfate in perlecan promotes mouse atherosclerosis: roles in lipid permeability, lipid retention, and smooth muscle cell proliferation. Papers, record 18596265. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/18596265

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Heparan sulfate in perlecan promotes mouse atherosclerosis: roles in lipid permeability, lipid retention, and smooth muscle cell proliferation.
PubMed
Journal
Circ Res
PubMed
Year
2008
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
87
iCite
Relative citation ratio, by iCite
1.99
iCite
Revised in PubMed
2026-01-28
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Tran-Lundmark KKarin
2Tran PKPhan-Kiet
3Paulsson-Berne GGabrielle
4Fridén VVincent
5Soininen RRaija
6Tryggvason KKarl
7Wight TNThomas N
8Kinsella MGMichael G
9Borén JJan
10Hedin UUlf

Source PubMed

Download CSV of authors

Topics23

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Apolipoproteins EMajor topic
AtherosclerosisMajor topic
Capillary PermeabilityMajor topic
Heparan Sulfate ProteoglycansMajor topic
Heparan SulfateMajor topic
Myocytes, Smooth MuscleMajor topic
TriglyceridesMajor topic
Actins
Animals
Antigens, CD
Antigens, Differentiation, Myelomonocytic
Aorta
Apolipoproteins B
Cell Proliferation
Crosses, Genetic
Disease Models, Animal
Humans
Inflammation
Lipoproteins, LDL
Mice
Mice, Knockout
Protein Binding
CD68 Molecule

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P01 HL018645NHLBI NIH HHSUnited StatesP01HL018645PubMed and NIHNIH RePORTER
18645PHS HHSUnited StatesPubMedPubMed

Download CSV of grants

References50

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
116011323Heparan sulfate: a complex polymer charged with biological activity.Chem Rev2005https://conductscience.org/library/papers/16011323PubMed
29020150Identification of sites in domain I of perlecan that regulate heparan sulfate synthesis.J Biol Chem1997https://conductscience.org/library/papers/9020150PubMed
314726411Molecular mechanism for changes in proteoglycan binding on compositional changes of the core and the surface of low-density lipoprotein-containing human apolipoprotein B100.Arterioscler Thromb Vasc Biol2004https://conductscience.org/library/papers/14726411PubMed
47159490Acidic glycosaminoglycan, lipid and water contents in human coronary arterial branches.Atherosclerosis1982https://conductscience.org/library/papers/7159490PubMed
512066187Subendothelial retention of atherogenic lipoproteins in early atherosclerosis.Nature2002https://conductscience.org/library/papers/12066187PubMed
611739273CD40 signaling and plaque instability.Circ Res2001https://conductscience.org/library/papers/11739273PubMed
78530367Lysolecithin-induced alteration of subendothelial heparan sulfate proteoglycans increases monocyte binding to matrix.J Biol Chem1995https://conductscience.org/library/papers/8530367PubMed
89719326Arterial heparan sulfate proteoglycans inhibit vascular smooth muscle cell proliferation and phenotype change in vitro and neointimal formation in vivo.J Vasc Surg1998https://conductscience.org/library/papers/9719326PubMed
911884291Accumulation of biglycan and perlecan, but not versican, in lesions of murine models of atherosclerosis.Arterioscler Thromb Vasc Biol2002https://conductscience.org/library/papers/11884291PubMed
10859561Suppression by heparin of smooth muscle cell proliferation in injured arteries.Nature1977https://conductscience.org/library/papers/859561PubMed
1115258195Atherosclerosis in perlecan heterozygous mice.J Lipid Res2004https://conductscience.org/library/papers/15258195PubMed
1216221765Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries.Proc Natl Acad Sci U S A2005https://conductscience.org/library/papers/16221765PubMed
1311122703Lipid mediators that modulate the extracellular matrix structure and function in vascular cells.Curr Atheroscler Rep1999https://conductscience.org/library/papers/11122703PubMed
1415186946Removal of heparan sulfate by heparinase treatment inhibits FGF-2-dependent smooth muscle cell proliferation in injured rat carotid arteries.Atherosclerosis2004https://conductscience.org/library/papers/15186946PubMed
1512514129Heparan sulfate chains of perlecan are indispensable in the lens capsule but not in the kidney.EMBO J2003https://conductscience.org/library/papers/12514129PubMed
169259586Subendothelial retention of lipoprotein (a). Evidence that reduced heparan sulfate promotes lipoprotein binding to subendothelial matrix.J Clin Invest1997https://conductscience.org/library/papers/9259586PubMed
179988721
Apolipoprotein E containing high density lipoprotein stimulates endothelial production of heparan sulfate rich in biologically active heparin-like domains. A potential mechanism for the anti-atherogenic actions of vascular apolipoprotein e.
J Biol Chem1999https://conductscience.org/library/papers/9988721PubMed
1810600481Localization of glycosaminoglycan substitution sites on domain V of mouse perlecan.Biochem Biophys Res Commun1999https://conductscience.org/library/papers/10600481PubMed
196324731Measurement in vivo of irreversible degradation of low density lipoprotein in the rabbit aorta. Predominance of intimal degradation.Arteriosclerosis1984https://conductscience.org/library/papers/6324731PubMed
2015117408Arterial heparan sulfate is negatively associated with hyperglycemia and atherosclerosis in diabetic monkeys.Cardiovasc Diabetol2004https://conductscience.org/library/papers/15117408PubMed

See all 50 referencesDownload CSV of references

Cited by57

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 87 citations.

PMIDTitleJournalYearIn PapersSource
41408231Arterial collagen IV and laminin levels associate with type 2 diabetes, glycemic control, major adverse cardiac events, and mortality in coronary bypass patients.Cardiovasc Diabetol2025https://conductscience.org/library/papers/41408231PubMed
40146858Modulation of host gene expression by the zinc finger antiviral protein.Proc Natl Acad Sci U S A2025https://conductscience.org/library/papers/40146858PubMed
39743565Apolipoprotein B-containing lipoproteins in atherogenesis.Nat Rev Cardiol2025https://conductscience.org/library/papers/39743565PubMed
39167826Smooth muscle-specific deletion of cellular communication network factor 2 causes severe aorta malformation and atherosclerosis.Cardiovasc Res2024https://conductscience.org/library/papers/39167826PubMed
38141085Mechano-chemo-biological model of atherosclerosis formation based on the outside-in theory.Biomech Model Mechanobiol2024https://conductscience.org/library/papers/38141085PubMed
37587506Knowledge fields and emerging trends about extracellular matrix in carotid artery disease from 1990 to 2021: analysis of the scientific literature.Eur J Med Res2023https://conductscience.org/library/papers/37587506PubMed
36986536Pentosan Polysulfate Affords Pleotropic Protection to Multiple Cells and Tissues.Pharmaceuticals (Basel)2023https://conductscience.org/library/papers/36986536PubMed
36140217Heparan Sulfate: A Regulator of White Adipocyte Differentiation and of Vascular/Adipocyte Interactions.Biomedicines2022https://conductscience.org/library/papers/36140217PubMed
35887981
TNF-α Inhibitors in Combination with MTX Reduce Circulating Levels of Heparan Sulfate/Heparin and Endothelial Dysfunction Biomarkers (sVCAM-1, MCP-1, MMP-9 and ADMA) in Women with Rheumatoid Arthritis.
J Clin Med2022https://conductscience.org/library/papers/35887981PubMed
35795646Smooth Muscle Cell-Macrophage Interactions Leading to Foam Cell Formation in Atherosclerosis: Location, Location, Location.Front Physiol2022https://conductscience.org/library/papers/35795646PubMed
35163259The Role of Matrix Proteins in Cardiac Pathology.Int J Mol Sci2022https://conductscience.org/library/papers/35163259PubMed
34626401Methods to Analyze the Effect of Diet-Derived Metabolites on Endothelial Inflammation and Cell Surface Glycosaminoglycans.Methods Mol Biol2022https://conductscience.org/library/papers/34626401PubMed
34433968APRIL limits atherosclerosis by binding to heparan sulfate proteoglycans.Nature2021https://conductscience.org/library/papers/34433968PubMed
34200914Potential Benefits of Flavonoids on the Progression of Atherosclerosis by Their Effect on Vascular Smooth Muscle Excitability.Molecules2021https://conductscience.org/library/papers/34200914PubMed
34105546The interaction of chondroitin sulfate with a lipid monolayer observed by using nonlinear vibrational spectroscopy.Phys Chem Chem Phys2021https://conductscience.org/library/papers/34105546PubMed
33817084Aberrant DNA Methylation Involved in Obese Women with Systemic Insulin Resistance.Open Life Sci2018https://conductscience.org/library/papers/33817084PubMed
33684447Macrophages bind LDL using heparan sulfate and the perlecan protein core.J Biol Chem2021https://conductscience.org/library/papers/33684447PubMed
33494649A Systems View of the Heparan Sulfate Interactome.J Histochem Cytochem2021https://conductscience.org/library/papers/33494649PubMed
33344181Proteomic analysis of anti-angiogenic effects by conbercept in the mice with oxygen induced retinopathy.Int J Ophthalmol2020https://conductscience.org/library/papers/33344181PubMed
33340050Smooth Muscle Cell-Proteoglycan-Lipoprotein Interactions as Drivers of Atherosclerosis.Handb Exp Pharmacol2022https://conductscience.org/library/papers/33340050PubMed

See all 57 cited byDownload CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
APOB338PubTator's text mininghttps://conductscience.org/library/genes/338NCBI Gene
BGN633PubTator's text mininghttps://conductscience.org/library/genes/633NCBI Gene
VCAN1462PubTator's text mininghttps://conductscience.org/library/genes/1462NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/18596265

GET https://conductscience.org/api/papers/v1/18596265/references?page=2